A BIOCENTURY report said the FDA’s budget proposal includes a policy wish list that would make pediatric priority review vouchers permanent and would reduce industry participation on advisory committees. The proposal is framed as a move to entrench pediatric priority review mechanisms while shifting how the agency structures external expert input. For developers, pediatric PRVs can materially affect development finance and incentives, particularly for sponsors planning pediatric sub-studies or lifecycle expansions. Changes to advisory committee structure could also influence review dynamics and the policy environment around how guidance is informed. Biotech leaders will likely focus on how the proposal evolves during budget negotiations and whether it signals broader regulatory tightening or rebalancing of influence.